Pipeline
Pipeline Overview
CNTY-101: Our lead candidate targeting CD19 for relapsed, refractory B-cell lymphoma CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, and an EGFR safety switch. IND submission is targeted mid 2022.
CNTY-101: Our lead candidate targeting CD19 for relapsed, refractory B-cell lymphoma CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy that has been engineered to express CD19 CAR, soluble IL-15, and an EGFR safety switch. IND submission is targeted mid 2022.
CNTY-103: Our CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma CNTY-103 represents our first clinical product candidate targeting a solid tumor. We believe targeting two antigen targets will help address tumor heterogeneity and antigen loss in GBM. We believe the clinical safety profile of engineered iNK cells may be optimal in GBM.
CNTY-103: Our CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma CNTY-103 represents our first clinical product candidate targeting a solid tumor. We believe targeting two antigen targets will help address tumor heterogeneity and antigen loss in GBM. We believe the clinical safety profile of engineered iNK cells may be optimal in GBM.
CNTY-102: Our CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies CNTY-102 will simultaneously target CD19 and CD79b and is designed to increase depth and durability of response by eliminating the effect of CD19 antigen loss that has been observed as a factor limiting treatment durability while targeting CD79b, an independently regulated, ubiquitous and validated B-cell target.
CNTY-102: Our CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies CNTY-102 will simultaneously target CD19 and CD79b and is designed to increase depth and durability of response by eliminating the effect of CD19 antigen loss that has been observed as a factor limiting treatment durability while targeting CD79b, an independently regulated, ubiquitous and validated B-cell target.
CNTY-104: CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia Under our collaboration with Bristol Myers Squibb, CNTY-104 will utilize our multi-specific iNK or iT cells for the treatment of AML.
CNTY-104: CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia Under our collaboration with Bristol Myers Squibb, CNTY-104 will utilize our multi-specific iNK or iT cells for the treatment of AML.
CNTY-106: CAR-iT or CAR-iNK multi-specific candidate for multiple myeloma Under our collaboration with Bristol Myers Squibb, CNTY-106 will utilize our multi-specific iNK or iT cells for the treatment of multiple myeloma.
CNTY-106: CAR-iT or CAR-iNK multi-specific candidate for multiple myeloma Under our collaboration with Bristol Myers Squibb, CNTY-106 will utilize our multi-specific iNK or iT cells for the treatment of multiple myeloma.
CNTY-107: Our γδ iT product candidate for the treatment of solid tumors expressing Nectin-4.
CNTY-107: Our γδ iT product candidate for the treatment of solid tumors expressing Nectin-4.
Solid Tumors
Hematologic Tumors